Genetic analysis of a novel antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice

Young-Cheol Lim 1,4†, Hyeongi Kim 1†, Sang Moo Lim 1,2 and Jin Su Kim 1,3*

Abstract

Background: Chemotherapy-induced alopecia has been well documented as a cause of distress to patients undergoing cancer treatment. Almost all traditional chemotherapeutic agents cause severe alopecia. Despite advances in the treatment of chemotherapy-induced alopecia, there is no effective treatment for preventing chemotherapy-induced alopecia.

Methods: In the present study, we investigated the potential role of a multi-target iron chelator, M30 in protecting against cyclophosphamide-induced alopecia in C57BL/6 mice implanted with an osmotic pump. M30 enhanced hair growth and prevented cyclophosphamide-induced abnormal hair in the mice. Furthermore, we examined the gene expression profiles derived from skin biopsy specimens of normal mice, cyclophosphamide-treated mice, and cyclophosphamide treated mice with M30 supplement.

Results: The top genes namely Tnfrsf19, Ercc2, Lama5, Ctsl, and Per1 were identified by microarray analysis. These genes were found to be involved in the biological processes of hair cycle, hair cycle phase, hair cycle process, hair follicle development, hair follicle maturation, hair follicle morphogenesis, regulation of hair cycle.

Conclusion: Our study demonstrates that M30 treatment is a promising therapy for cyclophosphamide-induced alopecia and suggests that the top five genes have unique preventive effects in cyclophosphamide-induced transformation.

Keywords: Alopecia, Cyclophosphamide, Chemotherapy, M30, Anti-oxidant, Microarray

Background

Alopecia (hair loss) is a common side effect of systemic cancer treatment using almost all traditional cytostatic chemotherapeutic agents (cyclophosphamide (CTX), doxorubicin, paclitaxel, etoposide), and it is often considered an inevitable consequence of chemotherapy. However, chemotherapy-induced alopecia (CIA) has a negative impact on the well-being of many cancer patients [1–4]. In addition, these patients often receive little more counseling than the advice to purchase a wig or other head covering during their cancer treatment [1, 5].

A number of procedures and reagents have been used to ameliorate the side effects of CIA. These include scalp tourniquets, scalp hypothermia, and treatments with minoxidil, AS101, or vitamin D [5–10]. Despite significant advances and efforts in research and development of CIA, no effective and reliable treatment has become available [11, 12], and the investigations have focused on chemotherapy-induced apoptosis and blockade of proliferation [10, 13, 14]. Thus, there remains a need for novel therapies for cancer patients suffering with hair loss. The development of new therapies would be facilitated by understanding the molecular mechanisms of hair loss in CIA.

The N-acetylcysteine (NAC) is an analog and a precursor of glutathione and is known to have a strong
antioxidant activity owing to its ability to enhance glutathione synthesis as well as act as an oxygen radical scavenger. NAC protected against doxorubicin-induced alopecia in mice [15], and CTX-induced alopecia in rats [16]. The combination of NAC and a biological response modifier, (ImuVert) induced protection against CIA by a combination of CTX and cytarabine (Ara C, cytosine arabinoside) in neonatal rat models [16]. The observation that antioxidants such as NAC protect against CIA in animals suggests the involvement of reactive oxygen species (ROS) in CIA. However, the mechanism by which ROS induces or promotes CIA has not been investigated [17].

The multi-target iron chelator, M30 [5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline] is a novel antioxidant and protective agent against oxidative stress in a spectrum of diseases. M30 was developed and studied for the prevention and treatment of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases, which included several therapeutic strategies, such as selective inhibition of monoamine oxidase-B, iron chelation, and anti-oxidation [18–20]. However, there is no report regarding its role in CIA.

In the present study, we aimed to determine the efficacy of M30 against CTX-induced alopecia. Since oxidative stress is one of the major pathological events during the progression of CIA, we hypothesized that M30 exert a beneficial effect against CTX-induced alopecia by inhibiting oxidative stress. We investigated the potential of M30 to stimulate hair re-growth during CTX-induced alopecia using depilated C57BL/6 mice. We further examined the gene expression profiles derived from skin biopsy specimens of depilated normal mice (Normal), CTX-treated depilated mice (CTX), and CTX-treated depilated mice continuously supplemented with M30 (MC). We then assembled a database of publicly available skin microarray samples representing CTX/normal, MC/CTX, and MC/normal groups. We now report that

![Fig. 1](image_url)
Fig. 2 (See legend on next page.)
five genes were differentially expressed in three microarray data sets from three different models and these genes were involved in hair cycle and hair follicle responses. These data provide an important foundation for further research into the identification of mechanisms that trigger hair follicle response in order to development of effective approaches for the management of hair loss induced by chemotherapy.

**Methods**

**Drugs**

CTX and the antioxidant, M30 were purchased as injectable commercial products (Sigma-Aldrich, USA). CTX and M30 were freshly dissolved in phosphate buffer saline (PBS; Gibco, USA) before injection.

**Animals**

Six-weeks-old female C57BL/6 mice were obtained from Orient Bio Inc. (Korea). The mice were maintained in temperature-controlled clean racks with a 12-h light/dark cycle. The mice were allowed to acclimatize for 1 week before the start of the experiment. All experiments were performed in accordance with the institutional guidelines of the Korea Institute of Radiological & Medical Sciences (KIRAMS).

**CTX-induced alopecia model**

The mice were depilated by shaving, followed by waxing using wax strips (Veet, USA); the skin was washed with PBS before experiments. At 9 days after depilation, the alopecia models were generated by a single intraperitoneal injection of CTX (120 mg/kg body weight) that was freshly prepared in PBS as previously described [21]. Before intraperitoneal injection of CTX, one group of mice (n = 5) was subcutaneously implanted with Alzet mini-osmotic pump (model 2004, DURECT, Cupertino, CA) containing M30 in PBS with a delivery rate of 1 mg/d/kg. The other normal (n = 5) and CTX treatment groups (n = 5) underwent sham operations without M30 supplement.

**Preparation of tissue samples and observation of hair follicles**

For the euthanization of mice, CO2 was injected at a rate of 10–30% per minute, that gradually fills the euthanasia chamber. Euthanization was performed by trained member. Then full-skin thickness samples of skin tissue were excised using scissors and immediately fixed using 4% paraformaldehyde in PBS for overnight at 4 °C. After fixation, the samples were incubated with 30% sucrose in PBS for 24 h at 4 °C. Then, the skin was embedded in O.C.T compound (Fisher Scientific, Pittsburg, USA) and frozen in liquid nitrogen. After freezing, the samples were stored in liquid nitrogen until further processing. Each specimen was sliced into 5 μm thickness section and observed by confocal microscopy. For microarray analysis, skin tissues from the mice were excised and immediately stored in liquid nitrogen in cryotubes until microarray analysis.

**Target labeling and hybridization to microarray**

For each RNA sample, synthesis of the target cRNA probes and hybridization were performed using Agilent’s Low Input QuickAmp Labeling Kit (Agilent Technologies, USA) according to the manufacturer’s instructions.

**Table 1** Number of regulated genes in skin of mice 2 weeks after administration of CTX with or without M30

| Condition          | Fold-change | P value | Mice (n) | Regulated genes (no.) |
|--------------------|-------------|---------|----------|-----------------------|
|                    |             |         |          | Total | Up | Down |
| CTX/Normal         | > 1.5       | < 0.05  | Normal (3), CTX (3) | 7722 | 3422 | 4300 |
| MC/Normal          | > 1.5       | < 0.05  | Normal (3), MC (3) | 1148 | 866  | 282  |
| MC/CTX             | > 1.5       | < 0.05  | CTX (3), MC (3) | 2753 | 1715 | 1038 |
| Condition 1        | > 1.5 (CTX/Normal) & < 0.666 (MC/CTX) | < 0.05 | Normal (3), CTX (3), MC (3) | 644  |
| Condition 2        | < 0.666 (CTX/Normal) & > 1.5 (MC/CTX) | < 0.05 | Normal (3), CTX (3), MC (3) | 241  |

*Normal is normal mice; CTX is cyclophosphamide-treated mice; MC is M30-supplemented cyclophosphamide-treated mice
Fig. 3 (See legend on next page.)
Briefly, each 25 ng total RNA and the T7 promoter primer were mixed and incubated at 65 °C for 10 min. The cDNA master mix (5x First strand buffer, 0.1 M DTT, 10 mM dNTP mix, RNase-Out, and MMLV-RT) was prepared and added to the reaction mixer. The samples were incubated at 40 °C for 2 h, and then dsDNA synthesis was terminated by incubating at 70 °C for 10 min. The transcription master mix was prepared as the manufacturer’s protocol (4x Transcription buffer, 0.1 M DTT, NTP mix, 50% PEG, RNase-Out, Inorganic pyrophosphatase, T7-RNA polymerase, and Cyanine 3-CTP). Transcription of the dsDNA was preformed by adding the transcription master mix to the dsDNA reaction samples and incubating at 40 °C for 2 h. Amplified and labeled cRNA was purified on an RNase mini column (Qiagen) according to the manufacturer’s protocol. The Labeled cRNA target was quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, USA). After verifying labeling efficiency, each 1650 ng of cyanine 3-labeled cRNA target was carried out the fragmentation of cRNA was fragmented by adding 10x blocking agent and 25x fragmentation buffer and incubating at 60 °C for 30 min. The fragmented cRNA was resuspended with 2x hybridization buffer and directly pipetted onto the assembled Agilent Mouse (V2) Gene Expression 4 × 44 K Microarray. The arrays were hybridized at 65 °C for 17 h using hybridization oven (Agilent Technologies, USA). The hybridized microarrays were washed as indicated in the manufacturer’s washing protocol (Agilent Technologies, USA).

Data acquisition and analysis

The hybridization images were analyzed by Agilent DNA Microarray Scanner (Agilent Technologies, USA) and data quantification was performed using Agilent Feature Extraction software 10.7 (Agilent Technologies, USA). The average fluorescence intensity of each spot was calculated and the local background was subtracted. Normalization of data and selection of fold-changed genes were performed using GeneSpringGX 7.3.1 (Agilent Technologies, USA). Normalization for Agilent one-color method was performed, which is Data transformation: Set measurements less than 5.0 to 5.0 and Per Chip: Normalize to 50th percentage. Each average normalized ratio was calculated by dividing the average of the control normalized signal intensity by the average of the test normalized signal intensity. Functional annotation of the genes was performed according to Gene Ontology™ (GO) Consortium (http://www.geneontology.org/index.shtml) by GeneSpringGX 7.3.1.

mRNA quantification by quantitative reverse transcription PCR (qRT-PCR)

Total RNA was extracted from mouse skin by using TRIzol reagent (Invitrogen, USA). Reverse transcription was performed on total RNA using SuperScript II reverse transcriptase (Invitrogen, USA) according to the manufacturer’s instructions. The resulting cDNA was amplified using the following primer pairs: (5’−→3’) Tnfrsf19 (Forward: ATGACCCTGATCAAAAGC, Reverse: TCCGATGTTGAAATAATCT), Ercc2 (Forward: AAGAGGAGCCCAAAAAAGACA, Reverse: CATCCGTGACATCAGTCA), Lama5 (Forward: TGCTTGAGGAAGCTGCTGAT, Reverse: CAC TGCCCTCTGGATTGTTGA), Ctsl (Forward: GCCATTGCCCTGGATTGTTG, Reverse: CTCATTACCGCTACCCATCA), Peli (Forward: TGCATGCTCCATTGTGAGT, Reverse: CCATGCCAGCCTGGATATCTT), GAPDH (Forward: GCCATTGCCCTGGATTGTTG, Reverse: ATGRAGGCATGAGCTGAAAT, Exon: ATGCACTGACAGCTGAAAT). Real-time PCR was performed on the StepOnePlus™ Real Time PCR System (Applied Biosystems, USA) using the SYBR Green PCR Kit (Applied Biosystems, USA), according to the manufacturer’s instructions. The thermal cycling conditions were 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and at optimal Tm (59 °C) for 30 s. The data were analyzed using the StepOne software v2.2.2 (Applied Biosystems, USA). The expression levels of each mRNAs were normalized to the endogenous control GAPDH and were calculated using the 2-ΔΔCt method.

Gene network construction and visualization

The BisoGenet plug-in [22] from Cytoscape software version 2.7.0 [23] was used to build and visualize the networks for the top five significant genes using the respective list of significant genes of the GO categories. All available data sources in BisoGenet (including BIOGRID, DIP, BIND, and others) were selected to generate the interactions.

Statistical analysis

Data processing was performed using Origin 6.1 (OriginLab, Northampton, MA). Statistical significance was determined using Student’s t-tests and ANOVA. A
p-value less than 0.05 was considered statistically significant.

Results
M30 prevents CTX-induced alopecia in C57BL/6 mice
To investigate whether M30 could prevent CTX-induced alopecia in mice, M30 was continuously infused using subcutaneously implanted osmotic pumps in depilated C57BL/6 mice. The hair was depilated on the dorsal surface of the normal and M30-supplemented mice, and then alopecia was induced by a single intraperitoneal injection of CTX (120 mg/kg body weight). The shaved skin of the telogen mice was pink and darkened with anagen initiation. Two weeks after injection of CTX, normal black hair was apparent in the normal mice, whereas abnormal gray hair was apparent in the CTX-treated mice. However, M30 supplement prevented the growth of abnormal gray hair in the CTX-treated mice (Fig. 1a). To further study the M30 normalized abnormal gray hair; we analyzed transverse sections of the dorsal skin from 2 weeks after injection of CTX. As suggested by the microscopic observation, M30 markedly increased the depth and size of the hair follicles, prevented the dystrophic changes seen with the CTX-treated mice, and normalized the appearance of the skin to that of normal mice (Fig. 1b).

Differential gene expression by CTX and M30
To investigate the alterations of gene expression in mouse skin during CTX and M30 treatment, we isolated total RNA from the skin of normal, CTX-treated mice, and M30 supplemented CTX-treated and we applied this RNA to the assembled Agilent Mouse (V2) Gene Expression 4 × 44 K Microarray, which contains 39,429 mouse genes. After hybridization, the microarray slide was scanned and analyzed. Each mouse gene was quantified according to its Cy3-labeled versus Cy5-labeled signal intensity. The graphs are shown (Fig. 2a) on a log scale using the Agilent Feature Extraction software 10.7 (Agilent Technologies, USA). These raw images were normalized by MA plot using locally weighted scatter plot smoothing (LOWESS) method. We applied the MA plot normalization process where $M = \log(constant)$ and $A = \frac{\log(Cy5) + \log(Cy3)}{2}$ is the average of the log intensities. A skewed form of ratio pattern before normalization changed to a linear pattern centered on zero after normalization. To understand which gene expression had changed, hierarchical clustering analysis was performed by using 9373 genes as shown in Fig. 2b.

Table 2 The five recurrently hair-related regulated genes after CTX and M30 treatment

| Group  | Gene symbol | Common name                          | GO annotation                        |
|--------|-------------|--------------------------------------|--------------------------------------|
|        |             |                                      | Hair cycle | Hair cycle phase | Regulation of hair cycle | Hair follicle development | Hair follicle maturation | Hair follicle morphogenesis |
| Condition 1 | Tnfrsf19 | Tumor necrosis factor receptor superfamily member 19 | Yes | Yes | Yes |         |         |         |
|         | Ercc2       | Excision Repair Cross-Complementation Group 2 | Yes | Yes |     | Yes | Yes |         |
|         | Lama5       | Laminin, Alpha 5 | Yes | Yes | Yes |         |         |         |
| Condition 2 | Ctsl  | Cathepsin L | Yes | Yes | Yes |         |         |         |
|         | Per1        | Period Circadian Clock 1 | Yes |       |     |         |         |         |

Differential gene expression by CTX and M30
To investigate the alterations of gene expression in mouse skin during CTX and M30 treatment, we isolated total RNA from the skin of normal, CTX-treated mice, and M30 supplemented CTX-treated and we applied this RNA to the assembled Agilent Mouse (V2) Gene Expression 4 × 44 K Microarray, which contains 39,429 mouse genes. After hybridization, the microarray slide was scanned and analyzed. Each mouse gene was quantified according to its Cy3-labeled versus Cy5-labeled signal intensity. The graphs are shown (Fig. 2a) on a log scale using the Agilent Feature Extraction software 10.7 (Agilent Technologies, USA). These raw images were normalized by MA plot using locally weighted scatter plot smoothing (LOWESS) method. We applied the MA plot normalization process where $M = \log(constant)$ and $A = \frac{\log(Cy5) + \log(Cy3)}{2}$ is the average of the log intensities. A skewed form of ratio pattern before normalization changed to a linear pattern centered on zero after normalization. To understand which gene expression had changed, hierarchical clustering analysis was performed by using 9373 genes as shown in Fig. 2b.

Table 3 Quantitative RT-PCR validation of microarray data

| Group  | Gene symbol | Common name | Microarray (fold) | qRT-PCR (fold) | Microarray vs qRT-PCR(p-value) |
|--------|-------------|-------------|-------------------|----------------|-------------------------------|
|        |             |             | CTX/Normal | MC/CTX | CTX/Normal | MC/CTX | CTX/Normal | MC/CTX |
| Condition 1 | Tnfrsf19 | Tumor necrosis factor receptor superfamily member 19 | 1.651 | 0.579 | 17.882 | 0.461 | 0.0058 | 0.431 |
|         | Ercc2       | Excision Repair Cross-Complementation Group 2 | 1.596 | 0.660 | 10.660 | 0.765 | 0.022 | 0.216 |
|         | Lama5       | Laminin, Alpha 5 | 2.033 | 0.443 | 7.160 | 0.478 | 0.062 | 0.654 |
| Condition 2 | Ctsl  | Cathepsin L | 0.588 | 2.119 | 0.620 | 1.758 | 0.884 | 0.367 |
|         | Per1        | Period Circadian Clock 1 | 0.333 | 2.586 | 0.730 | 1.260 | 0.133 | 0.119 |

*aNormal is normal mice; bCTX is cyclophosphamide-treated mice; cMC is M30-supplemented cyclophosphamide-treated mice*
Table 4 The altered genes after CTX and M30 treatment

| Angiogenesis                                      | Fold change | Aging                                      | Fold change | Cell proliferation | Fold change | Cell migration | Fold change |
|---------------------------------------------------|-------------|--------------------------------------------|-------------|-------------------|-------------|----------------|-------------|
| Gene symbol                                       | CTX/Normal  | MC/CTX                                     | CTX/Normal  | CTX/Normal        | CTX/Normal  | CTX/Normal     | CTX/Normal  |
| Condition 1*                                       |             | Condition 1                                |             | Condition 1       |             | Condition 1    |             |
| Shh                                               | 11.540      | 0.384                                      | Gjb6        | 9.359             | 0.258       | Shh            | 11.540      |
| Lef1                                              | 9.036       | 0.201                                      | Krt25       | 5.496             | 0.139       | Oca2           | 11.515      |
| Adm2                                              | 7.801       | 0.213                                      | Alox12      | 4.174             | 0.352       | Lef1           | 10.260      |
| Robo1                                             | 4.914       | 0.418                                      | S1c34a2     | 3.581             | 0.656       | Tspan1         | 10.093      |
| E2f8                                              | 4.537       | 0.307                                      | H2afx       | 3.312             | 0.422       | Lef1           | 9.036       |
| Condition 2*                                       |             | Condition 2                                |             | Condition 2       |             | Condition 1    |             |
| Tbx4                                              | 0.167       | 4.913                                      | Ift271a     | 0.165             | 1.675       | Dmbt1          | 0.122       |
| Spi1                                              | 0.163       | 3.851                                      | Ccl2        | 0.137             | 2.583       | Slc11a1        | 0.107       |
| Nov                                               | 0.162       | 4.204                                      | Ile6        | 0.086             | 4.170       | Enpep           | 0.103       |
| Ccl2                                              | 0.137       | 2.583                                      | Pot1b       | 0.067             | 2.010       | Gapt            | 0.086       |
| Enpep                                             | 0.103       | 8.165                                      | Ile6        | 0.052             | 4.141       | Il6             | 0.086       |
| Cell death                                        | Apoptosis   | Inflammatory response                      | RNA splicing|                   |             |                |             |
| Gene symbol                                       | Fold change | Gene symbol                                | Fold change | Gene symbol       | Fold change | Gene symbol    | Fold change |
| Condition 1*                                       |             | Condition 1                                |             | Condition 1       |             | Condition 1    |             |
| S100a8                                            | 11.647      | 0.555                                      | S100a8      | 11.647            | 0.555       | S100a8         | 11.647      |
| Shh                                               | 11.540      | 0.384                                      | Saa3        | 11.365            | 0.268       | Saa3           | 11.365      |
| Avp                                               | 10.850      | 0.317                                      | Camp        | 4.323             | 2.691       | Retnig          | 0.047       |
| Lef1                                              | 10.260      | 0.184                                      | Olr1        | 3.809             | 0.515       | Ddx39           | 2.238       |
| Gjb6                                              | 9.359       | 0.258                                      | Crhr1       | 3.421             | 0.434       | Rbmx            | 2.146       |
| Condition 2                                       | CTX/Normal  | MC/CTX                                     | CTX/Normal  | MC/CTX            | CTX/Normal  | MC/CTX         | CTX/Normal  |
| Ptgis                                             | 0.141       | 5.335                                      | Ptgis       | 0.141             | 5.335       | Pf4             | 0.084       |
| Gzma                                              | 0.139       | 8.220                                      | Gzma        | 0.139             | 8.220       | Ccr5            | 0.083       |
| Scn2a1                                            | 0.116       | 5.697                                      | Scn2a1      | 0.116             | 5.697       | Ccl7            | 0.073       |
| Ile6                                              | 0.086       | 4.170                                      | Ile6        | 0.086             | 4.170       | Ccl24           | 0.043       |
| Cd5l                                              | 0.059       | 3.309                                      | Cd5l        | 0.059             | 3.309       | Cxcl1           | 0.035       |
| Extracellular matrix                              | Immune response| Secretion                              |            |                |             |                |             |
| Gene symbol                                       | Fold change | Gene symbol                                | Fold change |                |             |                |             |
| Condition 1*                                       |             | Condition 1                                |             | Condition 1       |             | Condition 1    |             |
| Col10a1                                           | 21.343      | 0.043                                      | S100a8      | 11.647            | 0.555       | Chrl            | 15.534      |
| Shh                                               | 11.540      | 0.384                                      | Chrl        | 15.534            | 0.178       | Chrl            | 15.534      |
| Nav2                                              | 7.185       | 0.283                                      | Exo1        | 5.591             | 0.251       | Chrl            | 8.741       |
| Gpc5                                              | 3.730       | 0.549                                      | Smrs        | 4.538             | 0.452       | Nkd2            | 5.288       |
| Wnt5a                                             | 3.689       | 0.531                                      | Itgal       | 4.378             | 0.482       | Syt7            | 5.101       |
| Condition 2                                       | CTX/Normal  | MC/CTX                                     | CTX/Normal  | MC/CTX            | CTX/Normal  | MC/CTX         | CTX/Normal  |
| Dmbt1                                             | 0.122       | 3.491                                      | C1qa        | 0.057             | 8.083       | Kcnma1          | 0.151       |

Lim et al. BMC Cancer (2019) 19:149 Page 8 of 14
Hierarchical cluster analysis
Differences in the expression patterns of the protein-coding genes in the dorsal skin among normal mice, CTX-treated mice, and M30 supplemented CTX-treated mice were analyzed. By analyzing a genome-wide microarray, we observed significant transcriptional changes in mouse skin. We compared the CTX-treated mice with normal mice (CTX/Normal), M30 supplemented CTX-treated mice with normal mice (MC/Normal), and M30 supplemented CTX-treated mice with CTX-treated mice (MC/CTX), using a filter criterion of > 1.5-fold change with \( p < 0.05 \). We then compared the results of the skin samples obtained from these groups using the hierarchical clustering method in Cluster 3.0 software. The up-regulated genes were highly expressed in the experimental group (red), and the expression levels of the down-regulated genes were significantly decreased (green) (Fig. 2b). The cluster analysis shows that CTX and M30 induce differences in gene expression in the skin of the mice, and the stylized Venn diagram depicts the patterns of changes in the gene expression levels in each skin sample. The numbers of up-regulated, contra-regulated, and down-regulated genes that responded commonly or uniquely in response to the treatment are shown with red arrows, red texture, and blue arrows, respectively (Fig. 2c).

Results of the differentially expressed gene analysis
Based on Fig. 2b, we screened out 7722 genes (3422 up-regulated and 4300 down-regulated genes) in CTX/Normal, 1148 genes (866 up-regulated and 282 down-regulated genes) in MC/Normal, and 2753 genes (1715 up-regulated and 1038 down-regulated genes) in MC/CTX, using a filter criterion at least 1.5-fold change with \( p < 0.05 \). In addition, we rescreened recovered genes by M30 treatment against the CTX-regulated genes. The M30-down-regulated 644 genes against up-regulation by CTX were selected using a filter criterion of greater than 1.5-fold change (CTX/normal) and less than 0.666-fold change (MC/CTX) with \( p < 0.05 \). Moreover, the M30-up-regulated 241 genes against down-regulation by CTX were rescreened out using a filter criterion of less than 0.666-fold change (CTX/normal) and greater than 1.5-fold change (MC/CTX) with \( p < 0.05 \) (Table 1).

Gene ontology-based analysis
In further study, the functional annotation of the genes was assessed using a GO based biological property analysis (QuickGO; https://www.ebi.ac.uk/QuickGO/). The numbers of interesting genes were categorized as those being involved in the hair cycle, hair cycle phase, hair cycle process, hair follicle development, hair follicle maturation, hair follicle morphogenesis, and regulation of hair cycle in CTX/Normal, MC/CTX, and MC/Normal conditions, (Fig. 3a-c). Among these, the top five target genes, namely Tnfrsf19, Ercc2, Lama5, Ctsl, and Per1 were screened and the data are presented in Fig. 3d and Table 2. Tnfrsf19, Ercc2, Lama5, and Ctsl are associated with hair cycle, hair cycle process, and hair follicle development. And Per1, Ercc2, and Ctsl, are associated with regulation of hair cycle, hair follicle maturation, and hair follicle morphogenesis, respectively (Table 2). Taken together, these results show that CTX induces the differential expression of hair cycle, and hair follicle associated genes, which were recovered by M30 treatment.

Validation of microarray findings with quantitative RT-PCR (qRT-PCR)
To validate the microarray results, we quantified the expression of five target genes by quantitative RT-PCR (qRT-PCR) in normal, CTX, and MC sample. All qRT-PCR analyses were performed in samples previously used for the microarray experiments. Table 3 summarize the gene expression measurements of the five validated genes by qRT-PCR. We found that both methods (microarray analysis and qRT-PCR) detected similar patterns for the five target genes by condition 1 and condition 2. The respective \( p \)-values for the microarray and qRT-PCR data were significant at the 0.05 level (Table 3).

Gene network analyses
Following combined target prediction, overlapped gene deletion and validation, five genes were identified as targeted by M30 treatment, as shown in Fig. 3d and Table 2. To gain insight into the dynamics of these five significant genes and associated genes, we mapped the gene interactions network based on datasets derived from Proteomics or Genomics experiments. The five genes and their associated 25 genes are displayed in the gene network. The CTX up-regulated genes (Tnfrsf19, Ercc2, and Lama5) were shown in red nodes and down-pe...
regulated genes (Ctsl and Per1) in blue nodes, with 25 genes in the edges, respectively (Fig. 4). The entire network were verified for interactive visualization of gene interaction networks in the Cytoscape session data. The network can be loaded and visualized using Cytoscape (refer to the Methods section).

Discussion

During the last several decades, clinicians have attempted to develop nonpharmacological and pharmacological therapies to prevent alopecia from chemotherapy. A mechanical strategy, the scalp tourniquet has been applied in the past. The inflatable scalp tourniquet reduces blood supply to the scalp and hair follicles during chemotherapy in patients for prevention of CIA [7, 24]. However, concern has been expressed that this scalp cooling method promotes vasoconstriction to the scalp and inhibits temperature-dependent uptake of chemotherapeutic drugs in the hair follicle. In addition, pharmacologic strategies against CIA also have been applied to promote hair growth and prevent hair loss. The antioxidant, minoxidil is well known to promote hair growth in male-pattern baldness, and a local injection of minoxidil protected against cytarabine-induced alopecia [25], but not cyclophosphamide-induced alopecia in a neonatal rat model [26]. In previous studies, the various therapies have not provided any evidence of hair-loss prevention, and the effects of certain agents were dependent on the model being used [11].

The aim of this study was to investigate the ability of a novel antioxidant multi-target iron chelator M30, to promote hair growth in CTX-induced alopecia. In addition, we investigated the pathogenesis of CTX-induced alopecia and M30 protection against CTX-induced alopecia by comparing the gene expression profiles. In this study, we used C57BL/6 mice for CTX-induced alopecia models and global microarray profiling to study changes in the gene expression signature of mouse skin during CTX treatment with or without M30 treatment. We then compared the related gene expression profiles of the treated mice to those of the normal mice. CTX is responsible for several skin damages.

Our results demonstrate the preventive role of M30 against CTX-induced alopecia in C57BL/6 mice. M30 supplement therapy has been shown previously to improve cognitive impairment and reduce Alzheimer’s-like neuropathology in mouse models of Alzheimer’s disease [27, 28], but not CTX-induced alopecia. We systemically administered M30 using osmotic pumps to C57BL/6 mice to investigate the protective role of M30 against CTX-induced alopecia. The most important finding of our study was that M30-treated mice showed normal hair growth on the depilated skin of mice (Fig. 1).

![Interaction networks of five significantly changed hair-related genes after CTX and M30 treatment. Five target gene interaction networks were constructed by Cytoscape software (version 2.7.0; http://www.cytoscape.org). The top five target genes were screened according to the rank of target gene pair-specific context score. The genes in red nodes indicate CTX upregulated genes, blue nodes indicate downregulated genes, and the genes in edges indicate the interactive 25 genes.](image)
We further compared the molecular signature of CTX-treated mouse skin with and without M30 treatment with the skin of normal mice using global microarray profiling. cRNA microarray technology has become a widely used application for molecular profiling, and the techniques used to analyze the extensive quantity of data generated are variable. A hierarchical clustering heat map (Fig. 2b) and stylized Venn diagram

Fig. 5 The main functional categories showing significantly changed genes after CTX and M30 treatment. a–c The number of differentially expressed genes that were demonstrated in the following GO terms is indicated: angiogenesis-, aging-, cell proliferation-, cell migration-, cell death-, apoptosis-, inflammation-, RNA splicing-, extracellular matrix-, immune response-, and secretion-related genes. a CTX/Normal, b MC/CTX, and c MC/Normal
Fig. 6  Interactions networks of five significantly changed genes after CTX and M30 treatment. Target gene interaction networks were constructed by Cytoscape software (version 2.7.0; http://www.cytoscape.org). The genes in red nodes indicate CTX upregulated genes, blue nodes indicate downregulated genes, and the genes in edges indicate the interactive 25 genes.
(Fig. 2c) depict the patterns of changes in the gene expression levels in each sample. A detailed list of the gene signatures is presented in Table 2. We were interested in the general pattern of expression in the skin, changes in response to CTX treatment and the prevention of CTX-induced increased or decreased gene expression by M30.

Our study is the first to introduce the concept of systemic study by CTX and M30. By analyzing a genome-wide microarray, we observed significant transcriptional changes in 7722 genes of the CTX-treated skin when compared with that of normal skin using a filter criterion of at least 1.5-fold change with \( p < 0.05 \). Approximately 3422 genes were upregulated and 4300 genes were downregulated by CTX treatment. We further observed that M30 recovered genes against CTX transcriptional upregulation and downregulation. The 644 and 241 genes that were altered by CTX treatment but recovered by M30 treatment are shown in Table 1. These results indicate that M30 has preventive activities against CTX-induced pathological changes in the skin.

Functional annotation of the genes was assessed using GO-based biological property analysis (QuickGO; https://www.ebi.ac.uk/QuickGO/). The interesting genes were categorized as those involved in the hair cycle, hair cycle phase, hair follicle development, hair follicle maturation, hair follicle morphogenesis, and regulation of hair cycle (Fig. 3). Then, we validated expression of the five target genes at the transcript level with qRT-PCR data. In addition, we reported that gene interaction networks belonging to different modes such as activation, binding, and post-transcriptional modification, among others, led to the identification of new edges and ultimately contributed to identifying an M30 regulatory network in the CTX-treated skin. The derived network was visualized by Cytoscape (http://www.cytoscape.org/) as shown in Fig. 4. The hair-related GO and network analyses are shown in Figs. 3 and 4. Additionally, the unbiased GO and pathway analyses are shown in Figs. 5, 6 and Table 4.

**Conclusions**

These results provide new and useful information to support the epidemiological data showing that M30 replacement is a promising therapeutic strategy for CTX-induced alopecia, and that the top five genes, namely Tnfrsf19, Ercc2, Lama5, Ctsl, and Per1, might be involved in CTX-induced pathology. Although not directly clinically relevant, our findings suggest that these genes have a unique preventive role in CTX-induced alopecia. However, further studies, including histological analysis of skin specimens, are needed to confirm the results and to verify the protective effect of M30 against CTX treatment.

**Abbreviations**

CIA: Chemotherapy-induced alopecia; CTX: Cyclophosphamide; GO: Gene ontology; NAC: N-acetylcysteine; ROS: Reactive oxygen species

**Acknowledgements**

The authors appreciated Sangwoo Kim (Assistant Professor from Yonsei University) and Seong Duck Ryu (CEO form EBIOPGEN Inc) for helpful discussions for data analysis.

**Funding**

This work was supported by the Ministry of Health and Welfare (No. HO15C0003, PI: Jin Su Kim) and KIRAMS (No. 50536–2018; PI: Yong Jin Lee).

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

Conceived and designed the experiments: YL, JSK. Performed the experiments and analyzed the data: YL, HK. Wrote the paper: YL, JSK. Review the paper: JSK, LSM. All authors have read and approved the manuscript.

**Ethics approval and consent to participate**

All experiments were performed in accordance with the institutional guidelines of the Korea Institute of Radiological & Medical Sciences (KIRAMS).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Division of IR application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Gil, Gongneung-Dong, Nowon-Gu, Seoul 01812, Korea. 2Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea. 3Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), Seoul, Korea. *Research support team, ANDIVA Inc., Chuncheon, Korea.

**Received:** 6 April 2018 Accepted: 25 January 2019

**Published online:** 13 February 2019

**References**

1. van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW. Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. Eur J Oncol Nurs. 2013;17(5):336–40.
2. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology. 2010;19(7):701–9.
3. Hilton S, Hunt K, Emslie C, Salinas M, Zielbland S. Have men been overlooked? A comparison of young men and women’s experiences of chemotherapy-induced alopecia. Psychooncology. 2008;17(6):577–83.
4. Choi EK, Kim JR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103–10.
5. Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther. 2011;24(4):432–42.
6. Ayunin PK,Mahonot UA, Soininen KM, Paanenen PK, Ranta-Koponen PH, Saavalainen IE, Johansson RT. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96(2):271–3.
7. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol. 2005;16(3):352–8.
8. Sredni B, Gal R, Cohen U, Dazar JE, Givol D, Gaffer U, Motro B, Elyahu S, Albeck M, Lander HM, et al. Hair growth induction by the tellurium
immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB J. 2004;18(2):400–2.

9. Hidalgo M, Rinaldi D, Medina G, Griffin T, Turner J, Von Hoff DD. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anti-Cancer Drugs. 1999;10(4):393–5.

10. Schilli MB, Paus R, Menrad A. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol. 1998;111(4):598–604.

11. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12(8):543–9.

12. Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res. 2006;23(1):2505–14.

13. Yoon JS, Choi M, Shin CY, Paik SH, Kim KH, Kwon O. Development of a model for chemotherapy-induced alopecia: profiling of histological changes in human hair follicles after chemotherapy. J Invest Dermat. 2016;136(3):584–92.

14. Xie G, Wang H, Yan Z, Cai L, Zhou G, He W, Paus R, Yue Z. Testing chemotherapeutic agents in the feather follicle identifies a selective blockade of cell proliferation and a key role for sonic hedgehog signaling in chemotherapy-induced tissue damage. J Invest Dermatol. 2015;133(3):690–700.

15. D’Agostini F, Bagnasco M, Giunciuglio D, Albini A, De Flora S. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol. 1998;13(2):217–24.

16. Jimenez JJ, Huang HS, Yunis AA. Treatment with ImuVert/N-acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest. 1992;10(4):271–6.

17. Angustarunax P, Luanpapong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev. 2015;2015:795602.

18. Pimentel LS, Allard S, Do Carmo S, Weinreb O, Danik M, Hanzel CE, Youdim MB, Cuello AC. The multi-target drug M30 shows pro-cognitive and anti-inflammatory effects in a rat model of Alzheimer’s disease. J Alzheimers Dis. 2015;47(2):373–83.

19. Youdim MB. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol. 2013;22(1):1–10.

20. Shachar DB, Kahana N, Kampel V, Warschawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology. 2004;46(2):254–63.

21. Hendrix S, Handjiski B, Peters EM, Paus R. A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J Invest Dermatol. 2005;125(1):42–51.

22. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Brinas R. Bisogenet: a new tool for gene network building, visualization and analysis. BMC Bioinformat. 2010;11:91.

23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(1):2498–504.

24. Breed WP. What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss? Support Care Cancer. 2004;12(1):3–5.

25. Meidan VM, Touitou E. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Drugs. 2007;61(1):53–69.

26. Hussein AM. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol. 1995;34(7):470–3.

27. Zheng H, Fridkin M, Youdim M. New approaches to treating Alzheimer’s disease. Perspect. Med Chem. 2015;7(1):217–20.